Sevelamer Carbonate Tablet, Film Coated
Product Images NDC 60687-328

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 60687-328). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ahp32865

Sevelamer Carbonate 800 mg oral film-coated tablet shown in white, oblong shape. One side is imprinted with the code "J75" in black ink, while the opposite side is plain. This tablet is a prescription drug labeled by American Health Packaging.*

FDA Label Image

Blister (10)

Sevelamer Carbonate 800 mg film-coated tablet label from American Health Packaging. The label includes the product name, strength, dosage form, barcode, NDC number 60687-328, and placeholder text for lot number and expiration date. Each label is identical and arranged in a grid format for printing multiple labels on one sheet.*

FDA Label Image

Blister (4)

Four identical labels for Sevelamer Carbonate 800 mg film-coated tablets. Each label states the product name and strength, dosage form as tablet, packaging by American Health Packaging in Columbus, OH, includes placeholder text for lot number and expiry date, and displays a barcode with NDC beginning 60687-328.*

FDA Label Image

Carton (50)

Sevelamer Carbonate 800 mg film-coated tablets label from American Health Packaging. The label shows a 50-tablet count (5 x 10) and includes dosage strength, NDC 60687-328-65, and prescription only status. Additional text details inactive ingredients and storage instructions.*

FDA Label Image

Figure 2

A forest plot chart showing subgroup analysis comparing Sevelamer Carbonate and placebo. The chart includes statistical data such as LS mean differences and 95% confidence intervals across subgroups by screening BSA, baseline serum phosphorus, age, and dialysis status. The x-axis ranges from -5 to 5, indicating results favoring Sevelamer Carbonate on the left and placebo on the right.*

FDA Label Image

Figure 3

A line graph comparing the percentage of patients achieving various levels of reduction in serum phosphorus (mg/dL) between Sevelamer Hydrochloride and an Active Control. The X-axis indicates reduction in serum phosphorus from baseline, with negative values representing worsened increase and positive values representing improved reduction; the Y-axis shows the percentage of patients with reduction greater than or equal to the indicated value.*

FDA Label Image

Preprinted Carton

Sevelamer Carbonate 800 mg film-coated tablets packaging label from American Health Packaging. The label shows a 100-count package (25 x 4) and includes active ingredient strength information. The design features green and white colors with the American Health Packaging logo and distribution details from Columbus, Ohio.*

FDA Label Image

Structure

Chemical structure of Sevelamer Carbonate showing polymeric chains with primary amine groups, crosslinking groups, and bicarbonate ions. The diagram includes labeled components representing the extended polymer network with associated functional groups NH3+, NH2, NH, and OH.*

FDA Label Image

Image 01

A line graph depicting phosphorus change from baseline over 52 study weeks. The x-axis represents study weeks from 0 to 52, and the y-axis represents phosphorus change from baseline ranging from -5 to 2. Two lines compare Sevelamer Hydrochloride and an Active-Control treatment, showing phosphorus levels decreasing initially and then stabilizing over time for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.